RITTER PHARMACEUTICALS INC (59) | Uncategorized (10)

Recent Contracts

Novation Agreement among the Company, Qualigen, Inc. and University of Louisville Research Foundation, Inc. dated January 30, 2021 (Filed With SEC on May 14, 2021)
Novation Agreement among the Company, Qualigen, Inc. and University of Louisville Research Foundation, Inc. dated March 1, 2021 (Filed With SEC on May 14, 2021)
Technology Transfer Agreement dated as of October 7, 2020 between Qualigen, Inc. and Yi Xin Zhen Duan Jishu (Suzhou) Ltd (Filed With SEC on October 9, 2020)
Letter agreement (for payment date extension) between the Company and Sekisui Diagnostics, LLC dated June 23, 2020 (Filed With SEC on August 14, 2020)
Contingent Value Rights Agreement, dated May 22, 2020, by and among the Company, John Beck in the capacity of CVR Holders Representative and Andrew J. Ritter in his capacity as a... (Filed With SEC on May 29, 2020)
Form of Lock-Up Agreement (Filed With SEC on May 29, 2020)
Form of CVR Agreement, by and among Ritter Pharmaceuticals, Inc., Andrew Ritter, in his capacity as the initial CVR Holders Representative, and Andrew Ritter, in his capacity as a... (Filed With SEC on January 21, 2020)
Offer Letter Amendment by and between Ritter Pharmaceuticals, Inc. and Andrew J. Ritter, dated October 15, 2019 (Filed With SEC on October 15, 2019)
Offer Letter Amendment by and between Ritter Pharmaceuticals, Inc. and John W. Beck, dated October 15, 2019 (Filed With SEC on October 15, 2019)
Offer Letter Amendment by and between Ritter Pharmaceuticals, Inc. and Ira E. Ritter dated October 15, 2019 (Filed With SEC on October 15, 2019)